Why the study?
Does twice-daily higher-dose cyclophosphamide compared to once-daily lower-dose cyclophosphamide increase cardiotoxicity in bone marrow transplantation patients?
Does twice-daily higher-dose cyclophosphamide compared to once-daily lower-dose cyclophosphamide increase cardiotoxicity in bone marrow transplantation patients?
Twice-daily cyclophosphamide dosing regimens for bone marrow transplantation cause reversible ECG and LV mass changes, but systolic dysfunction is uncommon compared to historical high-dose once-daily regimens.
No takes yet. Share an insight, caveat, or question.
May support twice-daily higher-dose cyclophosphamide without acute LVEF decline in BMT; leaves open long-term effects and randomized comparisons.
Braverman et al. (1991) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: